STOCK TITAN

Allurion Technologies (ALUR) CEO Shantanu Gaur resigns; COO assumes operations

(Moderate)
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Allurion Technologies, Inc. stated that Chief Executive Officer and board member Shantanu K. Gaur, M.D. resigned his positions effective immediately on July 17, 2026. The company reported that his resignation was not the result of any disagreement regarding operations, policies or practices.

The board of directors has not appointed an interim or permanent Chief Executive Officer. Chief Operating Officer Ojas Buch is overseeing day-to-day operations and certain responsibilities previously performed by Dr. Gaur, while his title and compensation arrangements remain unchanged.

Positive

  • None.

Negative

  • Chief Executive Officer and director resignation with no interim or permanent successor yet appointed may create leadership uncertainty until a new CEO is selected.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
CEO resignation effective date July 17, 2026 Date Shantanu K. Gaur resigned as Chief Executive Officer and director
Report signature date July 23, 2026 Date the report was signed by Legal Officer Brendan M. Gibbons
Warrant share ratio 0.00378787 shares of common stock Each warrant to purchase 0.00378787 shares of Allurion common stock
Warrant exercise price $3,037.50 per share of common stock Exercise price for each share underlying the ALUR WS warrants
Emerging growth company regulatory
"An issuer that qualifies as an "Emerging growth company" under Rule 12b-2"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
pre-commencement communications regulatory
"Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act"
exercise price financial
"Warrants ... each at an exercise price of $3,037.50 per share of common stock"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
board of directors regulatory
"resignation ... as a member of the Company's board of directors"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What executive leadership change did Allurion Technologies (ALUR) report?

Allurion Technologies reported that CEO and director Shantanu K. Gaur, M.D. resigned effective July 17, 2026. His resignation was effective immediately, and the board has not yet appointed an interim or permanent CEO, while the COO has assumed oversight of day-to-day operations.

Did Shantanu Gaur resign from Allurion Technologies (ALUR) due to disagreements?

The company stated that Dr. Gaur’s resignation was not the result of any disagreement with Allurion or its board. It specifically referenced the absence of disagreements regarding the company’s operations, policies or practices in connection with his decision to step down.

Who is overseeing operations at Allurion Technologies (ALUR) after the CEO resignation?

Chief Operating Officer Ojas Buch is overseeing Allurion’s day-to-day operations following Dr. Gaur’s resignation. He has assumed certain responsibilities previously handled by the CEO, while his formal title as COO and his compensation arrangements have not been changed in connection with these duties.

Has Allurion Technologies (ALUR) named a new CEO or interim CEO?

As of this report, Allurion’s board has not appointed an interim or permanent Chief Executive Officer. Instead, the existing Chief Operating Officer is temporarily handling day-to-day operational oversight and some former CEO responsibilities while the board evaluates longer-term leadership arrangements.

When did the CEO resignation at Allurion Technologies (ALUR) take effect?

The resignation of CEO and director Shantanu K. Gaur, M.D. took effect immediately on July 17, 2026. This effective date marks when he ceased serving as Chief Executive Officer and board member, with operational oversight transitioning to the company’s Chief Operating Officer.
0001964979falseNONENONE0001964979alur:CommonStockParValue00001PerShareMember2026-07-172026-07-170001964979alur:WarrantsToPurchase000378787SharesOfCommonStockEachAtAnExercisePriceOf303750PerShareOfCommonStockMember2026-07-172026-07-1700019649792026-07-172026-07-17

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 17, 2026

 

 

Allurion Technologies, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-41767

92-2182207

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

11 Huron Drive

 

Natick, Massachusetts

 

01760

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (508) 647-4000

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common stock, par value $0.0001 per share

 

ALUR

 

N/A

Warrants to purchase 0.00378787 shares of common stock, each at an exercise price of $3,037.50 per share of common stock

 

ALUR WS

 

N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On July 17, 2026, Shantanu K. Gaur, M.D. notified Allurion Technologies, Inc. (the “Company”) of his resignation as Chief Executive Officer of the Company and as a member of the Company's board of directors (the “Board”), in each case effective immediately.

Dr. Gaur's resignation was not the result of any disagreement with the Company or the Board on any matter relating to the Company's operations, policies or practices.

In connection with Dr. Gaur's resignation, the Board has not appointed an interim or permanent Chief Executive Officer. Ojas Buch, the Company's Chief Operating Officer, will oversee the Company's day-to-day operations, including certain responsibilities previously performed by Dr. Gaur. Mr. Buch’s title and compensation arrangements have not been modified in connection with these responsibilities.

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

Date:

July 23, 2026

By:

/s/ Brendan M. Gibbons

 

 

 

Name: Brendan M. Gibbons

Title:Chief Legal Officer

 


Filing Exhibits & Attachments

1 document